DBV Technologies (France) a clinical-stage drug:device biopharma company focused on non invasive immunotherapy delivery for food allergies, closed a $25.5M Series C financing. Participants include InnoBio Fund, Lundbeckfond Ventures, ALTO Invest, Sofinnova Partners, ALK Abello and Apax Partners.